Department of Surgery, Keio University, School of Medicine, Tokyo, Japan.
Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan
Anticancer Res. 2021 Feb;41(2):783-794. doi: 10.21873/anticanres.14830.
BACKGROUND/AIM: The inflammatory cytokine IL-8 and its receptor CXCR2 are key signalling pathway molecules in cancer development. We hypothesized that IL-8/CXCR2 signalling promotes tumour progression in oesophageal squamous cell carcinoma (ESCC) patients.
We examined the relationship between IL-8/CXCR2 expression and clinicopathological factors by immunohistochemistry in samples from 63 patients with resectable ESCC. The effects of IL-8/CXCR2 signalling on cell proliferation and gene expression were examined in vitro and in vivo using ESCC cell lines.
Increased IL-8/CXCR2 signalling was associated with shorter overall survival (p<0.05) and recurrence-free survival (p<0.05) in ESCC patients. Multivariate analysis identified IL-8/CXCR2 expression as a prognostic factor for surgically treated ESCC (p<0.05). In vitro, IL-8 exposure or over-expression significantly enhanced ESCC cell proliferation. SB225002, a CXCR2-specific antagonist, and IL-8 siRNA significantly suppressed cell proliferation.
IL-8/CXCR2 expression is an independent prognostic factor for surgically treated ESCC, and IL-8/CXCR2 signalling contributes to ESCC cell proliferation.
背景/目的:炎症细胞因子 IL-8 和其受体 CXCR2 是癌症发展中关键的信号通路分子。我们假设 IL-8/CXCR2 信号促进食管鳞状细胞癌(ESCC)患者的肿瘤进展。
我们通过免疫组织化学方法检查了 63 例可切除 ESCC 患者样本中 IL-8/CXCR2 表达与临床病理因素之间的关系。我们使用 ESCC 细胞系在体外和体内研究了 IL-8/CXCR2 信号对细胞增殖和基因表达的影响。
IL-8/CXCR2 信号的增加与 ESCC 患者的总生存(p<0.05)和无复发生存(p<0.05)较短有关。多变量分析确定 IL-8/CXCR2 表达是手术治疗 ESCC 的预后因素(p<0.05)。在体外,IL-8 暴露或过表达显著增强了 ESCC 细胞的增殖。CXCR2 特异性拮抗剂 SB225002 和 IL-8 siRNA 显著抑制了细胞增殖。
IL-8/CXCR2 表达是手术治疗 ESCC 的独立预后因素,IL-8/CXCR2 信号促进 ESCC 细胞增殖。